SMAD2 and gastric cancer: The overall survival (OS) of the HER2-positive gastric cancer patients with p-Smad2 and c-Met expression (n = 13) was significantly poorer than that of the patients with p-Smad2-negative and/or c-Met-negative expression (n = 30) (p = 0.030) (Fig. 5A).